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A B S T R A C T
Since the identification of severe illness caused by the novel coronavirus SARS-CoV-2, the role of the
host immune system in causing disease has attracted widespread attention, along with intense inter-
est in medical interventions that target the host immune response. A wide variety of agents have been
proposed to treat a cytokine storm in coronavirus disease 2019 (COVID-19), but so far, only one class
of medications, corticosteroids, has proved useful. In recent decades, experimental therapies for cyto-
kine storms have been tried and mostly failed to help patients with severe sepsis and other infections.
We summarize this history in order to frame expectations for novel interventions in COVID-19 and to
bring an evolutionary medicine perspective to the concept of cytokine storms and their treatment.
Lay Summary: Many treatments for COVID-19 are aimed at calming a cytokine storm, a dangerous im-
mune overreaction to the infection. Treating cytokine storms has been tried for decades in sepsis and
other viral illnesses, but these treatments most often do not work. We explain why cytokine storms
should be rare, and what special evolutionary circumstances can cause them to occur.
K E Y W O R D S : SARS-CoV-2; Covid-19; cytokine storm; corticosteroids; immunity
INTRODUCTION
With new and emerging infections, it can sometimes
appear that the immune response does more harm
than good. Excessive and dangerous immune
responses have been cited in hantavirus pulmonary
syndrome, Ebola virus [1], avian flu, H1N1 influenza
[2], SARS1 and most recently, COVID-19 [3]. In the
sickest COVID-19 patients, pathology has been
described as an immune system gone awry, with an
out-of-control inflammatory response driven by an
apparent cytokine storm.
Cytokine storms—defined as a dysregulated,
exaggerated and misdirected immune response
accompanying excessive release of inflammatory
cytokines—first appeared in the medical literature
three decades ago in a report concerning graft ver-
sus host disease [4]. The term cytokine storms as
applied to infectious disease has centered on viral
illnesses [5] and influenza in particular [6, 7], along
with septic shock caused by non-viral pathogens.
Interest in cytokine storms has recently
gained much attention with the COVID-19 pan-
demic [3].
VC The Author(s) 2021. Published by Oxford University Press on behalf of the Foundation for Evolution, Medicine, and Public Health. This is an Open
Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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A Science magazine profile included this quotation by the vir-
ologist Peter Piot, describing his personal experience with
SARS-CoV-2 infection:
I turned out to have an organizing pneumonia-
induced lung disease, caused by a so-called cytokine
storm. It’s a result of your immune defense going
into overdrive. Many people do not die from the tis-
sue damage caused by the virus, but from the exag-
gerated response of their immune system, which
doesn’t know what to do with the virus. I’m still
under treatment for that, with high doses of cortico-
steroids that slow down the immune system [8].
Since that article was published, the corticosteroid dexa-
methasone has shown promising results in severe COVID-19
[9]. In the RECOVERY trial, infected patients requiring supple-
mentary oxygen or mechanical ventilation who were random-
ized to dexamethasone had improved survival [9]. Since
corticosteroids reduce inflammatory responses, the findings of
RECOVERY appeared to validate the hypothesis that cytokine
storms contribute to COVID-19 mortality.
The idea that excess inflammation kills COVID-19 patients is
paradoxical because robust immunity has been linked with sur-
vival (i.e. in young patients and female patients), while impaired
immunity has been associated with higher mortality (i.e. in im-
munocompromised patients and the aged) [10, 11].
Furthermore, immune overdrive should tend to be uncommon
because of strong selective pressures to pare back deleterious
immune responses over time. The observation that dexametha-
sone is less effective in less severely ill patients, along with the
failure of other anti-cytokine agents in COVID-19, suggests that
immune defenses in COVID-19 are complex and should be con-
sidered a double-edged sword. An immune response needs to
be matched to the infectious challenge in order to maximize
host fitness—too much or too little might result in the death of
the host [2].
The history of immune modulating medications in infectious
disease is instructive when considering treatments aimed at
calming a cytokine storm in COVID-19. Some pharmaceutical
interventions under study for COVID-19 have analogs that were
previously used to treat sepsis and septic shock, with the guid-
ing hypothesis that restraining hyperinflammation would bene-
fit survival. However, despite the support of promising
preclinical results and a clear-cut mechanistic rationale, the
vast majority of immune modulating treatments in sepsis have
not improved survival [12]. It has been crucially reported that
the cytokine profile in plasma of severe COVID-19 infection
does not differ significantly from acute respiratory distress syn-
drome (ARDS) and sepsis [13]. This is an important observation
in that it tells us that previous research on ARDS and sepsis
treatments is potentially relevant to COVID-19 cases.
Here, we critically examine the origin of the ‘cytokine storm’
concept and discuss how this notion influences patient treat-
ment and research priorities. We describe the outcome of trials
aimed at suppressing hyperinflammation in sepsis and other
infections. Finally, we analyze this potential dysregulation of the
immune system in the context of evolutionary medicine. When
might we expect that the immune system, having evolved to
protect us from infection, should instead go out of control and
kill us?
TREATING CYTOKINE STORMS
Several investigators have proposed that hyperinflammation is
a primary cause of severe COVID-19 and thus have advocated
for therapeutic interventions against cytokine storms [3, 14]. A
wide variety of immunosuppressive medications are being con-
sidered for COVID-19, including corticosteroids, Janus kinase
inhibitors, and anti-cytokine treatments (Fig. 1). If excessive
cytokine release is induced by COVID-19, as these investigators
suggest, it follows that anti-cytokine treatments, such as inhibi-
tors of the pro-inflammatory cytokines TNF-a and interleukin
(IL)-6, should be beneficial [15].
Anti-cytokine monoclonal antibodies
Many immunomodulatory drugs being proposed for COVID-19
were originally developed for and tested in sepsis. However,
early promising results of anti-cytokine treatments in sepsis led
to disappointing large-scale randomized controlled trials in sep-
sis (Fig. 2). Many agents have subsequently found a role in
treating chronic inflammatory conditions, including rheumatoid
arthritis and Crohn’s disease.
Damas et al. [16] in 1992 pointed out that cytokine levels, par-
ticularly TNF-a, IL-1b and IL-6 were associated with mortality in
severe sepsis. In particular, they wrote:
IL-6 correlated well with APACHE II score, and the
mortality rate increased significantly in the group of
Figure 1. Cytokine targets of treatment for COVID-19. Antigen-presenting
cells are a key source of pro-inflammatory cytokines and chemokines in
COVID-19 infection. A variety of pharmaceutical agents that inhibit cyto-
kines are under investigation.
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patients who presented with IL-6 serum level above
1000 pg/ml.
These findings ushered in an era of intense interest in lower-
ing IL-6, TNF-a and other pro-inflammatory cytokines in order
to stave off sepsis mortality. Subsequently in 1996, Fisher et al.
published a randomized controlled trial in NEJM of the tumor
necrosis factor receptor fusion protein (TNFR: Fc), aimed at
reducing TNF-a signaling [17]. In that trial, patients treated with
TNFR: Fc unexpectedly showed increased mortality compared
with placebo [17].
Other trials also had negative results, including the RAMSES
trial of antibody treatments directed at TNF-a [18]. Reinhart
et al. [18] wrote:
The repeated failures of even large sepsis trials to
demonstrate more than a favorable trend in sur-
vival benefit with anti-TNF-a therapy raises the
possibility that expectations for this therapeutic ap-
proach may have been exaggerated.
Because sepsis was not seen as an appropriate target for
these drugs, agents developed out of this research program
were repurposed for autoimmune diseases and are known col-
lectively as disease-modifying antirheumatic drugs (DMARDs).
This use comes with an important caveat. When compared with
lacebo, DMARDs have been shown to increase the risk of severe
infection [19].
A recent review surveyed the landscape of immune modulat-
ing drugs in COVID-19 and concluded that ‘there is no evidence
of the beneficial impact of IL-6 inhibitors on the modulation of
COVID-19’ [20]. One such drug, sarilumab has been shown to
inhibit IL-6 mediated signaling and is approved for rheumatoid
arthritis. On 1 September 2020, its manufacturers reported that
the drug failed to reduce mortality or shorten hospital stays in
COVID-19 [21]. Tocilizumab is another anti-IL-6 monoclonal
antibody agent approved by the FDA for rheumatoid arthritis.
The advanced phase III COVACTA study of tocilizumab in hos-
pitalized patients with COVID-19 pneumonia failed to meet its
primary endpoint of improved clinical status [22]. The
COVACTA trial is one of five randomized trials on tocilizumab
that were summarized in a recent JAMA editorial [23]. None of
these trials reported a mortality benefit at 28 or 30 days. The
majority did not meet their prespecified primary outcome meas-
ure for clinical efficacy [23].
Corticosteroids
Before COVID-19, influenza was the best studied viral infection
regarding the use of corticosteroids. Because levels of pro-
inflammatory cytokines are elevated in severe cases of influ-
enza, corticosteroids have been extensively used in critically ill
patients with flu [24, 25]. Brun-Buisson et al. [26] showed no
benefit to corticosteroids in H1N1 influenza A ARDS, and this
observational trial suggested higher mortality from early cor-
ticosteroid use. A recent review of immunomodulatory agents
for influenza concluded: ‘currently there are no immunomodu-
latory agents that have been conclusively proven to be of benefit
in severe influenza’ [24]. A 2019 Cochrane meta-analysis sug-
gested increased mortality in patients with influenza receiving
adjunctive corticosteroids. This study—including 21 random-
ized controlled trials, including 15 involving the 2009 H1N1
influenza—found a significant association between corticoste-
roids and increased mortality (odds ratio) 3.90, 95% CI
2.31–6.60; I2 ¼ 68%). That report also included a pooled ana-
lysis of seven studies suggesting an increased risk of hospital
acquired infection which may be responsible for the increased
incidence of death.
In contrast to these earlier trials, the recently published
RECOVERY trial showed a reduction in mortality at 28 days
among hospitalized COVID-19 patients who were randomized
to oral or IV dexamethasone compared with placebo. Improved
survival in the dexamethasone group occurred only in severe
COVID-19 cases requiring supplemental oxygen or mechanical
ventilation [9]. There was no survival benefit, and a possibility of
harm, in patients with less severe infection [9].
Improved survival with corticosteroids in COVID-19 may
occur in some adults with ARDS [27], raising the possibility that
a corticosteroid benefit in COVID-19 may accrue mostly to ven-
tilated patients with decompensated lung status. However, evi-
dence for corticosteroids in ARDS is mixed [28, 29] and a recent
secondary analysis of a 2015 randomized controlled trial involv-
ing 745 patients with ARDS showed no mortality benefit from
corticosteroids [30]. In sepsis, corticosteroids have also shown
Figure 2. Anti-inflammatory treatments in sepsis and COVID-19. Evidence
supports using the corticosteroid dexamethasone in severe COVID-19.
However, in the vast majority of trials of human sepsis and COVID-19, anti-
inflammatory medications have not improved survival.
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mixed results, but the largest multicenter randomized con-
trolled trial showed no improvement in short- or long-term sur-
vival [31].
In contrast to the RECOVERY trial, several observational
studies involving COVID-19 patients with pre-existing cortico-
steroid use suggest potential harms from this class of medica-
tion. In COVID-19, systemic corticosteroids in patients with
inflammatory bowel disease had a 6.9 increased odds of mortal-
ity [32]. Furthermore, a recent observational study found that
patients with chronic obstructive pulmonary disease who were
previously prescribed inhaled corticosteroid treatment were at
an increased risk of death due to COVID-19 infection. Similarly,
it found that asthma patients prescribed a high dose of inhaled
corticosteroids were at increased risk of COVID-19 related
death compared with those given a low or medium dose.
Although these results could be explained by confounding fac-
tors such as comorbid disease severity, it does complicate the
picture of corticosteroid use as generally protective [33].
Although the RECOVERY trial showed a benefit to corticoste-
roids in ventilated COVID-19 patients, a trend to increased mor-
tality in lower acuity COVID-19 cases in the same trial raises
questions about which patients are likely to benefit versus suffer
harm from their use [9]. Whether steroids help or hurt, for which
indications, in what doses, and at what time in the disease
course, continue to be sources of controversy. However, it is
important to heed the lessons of corticosteroid trials in other
severe viral infections and sepsis. We should expect tradeoffs
from drugs like corticosteroids that have powerful pleiotropic
effects on the immune system.
IMMUNE OVERSHOOT—EVOLUTIONARY
CONSIDERATIONS
With the exception of corticosteroids in severe adult COVID-19,
immune modulating drugs in sepsis and severe viral infections
have been mostly ineffective or they have proven harmful.
These observations suggest excessive immune responses may
be more infrequent than commonly supposed. However, there
remains evidence that occasionally immune systems do, in fact,
overshoot. Several possibilities exist to explain immune dysre-
gulation and self-harm.
Smoke detector principle and immune brinksmanship
The smoke detector principle has been proposed as an explan-
ation for responses that are out of proportion to the apparent
threat. Biological systems can overshoot in various scenarios,
such as panic, and in certain immune responses [34]. The
smoke detector principle suggests that an optimally regulated
system can produce events that are excessive, even sometimes
maladaptive for an individual. The evolution of threat detection
and response systems is expected to produce occasional over-
reactions. A smoke detector that is useful for a house fire pro-
vides an analogy: to get this kind of reliability needed to protect
us, we are willing to accept occasional false alarms. Using this
analogy, Nesse and Schulkin [35] have argued that ‘inflamma-
tory responses to infections are relatively inexpensive compared
with the catastrophe that could result from an inadequate re-
sponse’. Although we would expect that selection would dis-
favor needlessly costly or lethal immune responses (see Box 1),
the smoke detector principle may explain some ostensibly ex-
cessive immune responses during severe infections [36]. Like a
smoke detector, toll-like receptors are triggered by danger sig-
nals (alarmins) and pathogen-associated molecular patterns
(PAMPs), generating an inflammatory cascade that can both
help and harm the host. Activation of TLR-4 by bacterial lipo-
polysaccharide, e.g. is sufficient to cause life threatening sepsis
syndrome even when live bacteria are absent [37]. Consistent
with expectations of the smoke detector principle, blocking
TLR4 activation by lipopolysaccharide fails to improve, and
sometimes worsens, host mortality during infections [38, 39].
These observations suggest that recognition of lipopolysacchar-
ide is an evolutionarily conserved response that confers an
adaptive benefit, on average, to the host [40]. A key implication
of the smoke detector principle is that blocking defenses, even
those that appear excessive, can have negative unintended clin-
ical consequences.
Immune brinksmanship is another proposal to explain the
evolutionary persistence of apparently harmful immune
responses [41]. In this model, the host undertakes a risky gam-
ble when mounting an immune response against infection that
involves substantial harm to both the host and the pathogen
[41]. However, the host gambles that those harms will be dis-
proportionately directed to pathogens. The analogy is one of
trade sanctions in which a country might undertake an econom-
ically damaging stoppage of trade with a competitor, with the
calculation that the competitor will bear the brunt of the injury.
For immune responses during infections, selection acting on
hosts is expected to minimize, but not eliminate, the costs suf-
fered by hosts. A casino provides another analogy for immune
brinksmanship. As in a casino, where the odds are in favor of
the house, the odds of immune brinksmanship favor the host.
However, in casinos the house sometimes loses. Immune
brinkmanship would be most protective when there has been
sufficient evolutionary time for selection to fine tune it. This is
not true for novel SARS-CoV-2, and some deaths may represent
an immune gamble gone bad.
Mismatch
Mismatch occurs when organisms are subjected to novel envi-
ronments that are different from the environments that their
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ancestors evolved in and that their physiology evolved to expect.
One example is the modern use of antibiotics and the Jarisch
Herxheimer (JH) reaction. The JH reaction was named after two
dermatologists in 1902 who noticed worsening skin rashes in
patients with syphilis treated with mercury compounds. When
penicillin became the treatment of choice for syphilis, the JH re-
action was typified by a rash, and also fever, hypotension and
sometimes death. The immune-mediated response of JH is
reported in other spirochete infections, including Lyme disease
and relapsing fever, and is linked with sudden increase in pro-
inflammatory cytokines, including tumor necrosis factor [42].
Immune overshoot caused by antibiotics is a consequence of
the sudden unmasking of bacterial antigens caused by dying
and dead spirochetes. Spirochete molecular patterns that are
otherwise inaccessible to the host immune system [43] initiate
widespread antibody and complement-driven immune
responses, and an apparent cytokine storm. The JH reaction
only occurs with exogenous antimicrobials, suggesting that this
cytokine storm occurs because a mismatch involving modern
medical treatment. This response also highlights the smoke de-
tector principle, since we expect that evolution would tend to
favor threat detection and effector systems that err on the side
of being more sensitive.
Mismatch and COVID-19—host switching
Inexperience of the human immune system with novel corona-
virus is another mismatch that might lead to sub-optimal im-
mune responses. Crespi [44] has argued that this mismatch is
the primary explanation for the hyperinflammatory response to
COVID-19. Bats are the proposed reservoir hosts for many
emerging viruses; the original host of SARS-CoV-2 is thought to
be a horseshoe bat. Humans may not have had sufficient time
to evolve optimal strategies to cope with this bat-adapted virus
[44]. When compared with humans, viral infections in bats often
lack overt signs of disease. Bats may tolerate coronavirus infec-
tions better in part because they have higher constitutive ex-
pression of interferon (IFN)-a [45]. Two competing potential
strategies exist for hosts to cope with infections—immune re-
sistance and immune tolerance [46]. The idea of a fatal cytokine
storm in COVID-19 dovetails with the notion that survival out-
comes would be better if the host reduced anti-pathogen effort,
a concept known as immune resistance, and instead engaged
in a strategy termed immune tolerance [47, 48]. We might ex-
pect a host response that involves excess resistance and insuffi-
cient tolerance for a novel pathogen. This would be particularly
the case if tolerance mechanisms are harder solutions that take
more time to evolve than general-purpose resistance strategies.
In addition, experimental and theoretical work suggests that
that older organisms are at greater risk for mismatch-related
pathology [49]. The notion that for virulent SARS-CoV-2 insuffi-
cient time has existed for selection to modulate immune
responses with age-dependent effects deserves further study.
Tradeoffs involving other pathogens
The host may face a tradeoff during COVID-19 infection when
they are infected at the same time by multiple other pathogens.
Coinfection also tends to select for higher virulence in parasites
generally and might be expected to worsen the severity of
COVID-19 [50]. Chronic infections and multiple infections in
COVID-19 are commonly reported [51]. Many people are chron-
ically infected with herpesviruses and other pathogens that are
potent inhibitors of antiviral immunity [52], including the IFN
responses that are a key defense against SARS-CoV-2.
Consequently, some viral coinfections might worsen COVID-19
outcomes. Similarly, coinfection with bacterial or fungal patho-
gens may trigger maladaptive immune responses in COVID-19,
Box 1. Why out of control immune responses should be rare in the infected host
Excessive immune responses face strong selection to reduce their costly and self-injurious effects.
Encounters with pathogens are problematic for hosts because infection decreases the Darwinian fitness of the host. Decreased host fitness takes
two forms (i) direct injury as a result of viruses, for instance, commandeering the replicative machinery of host cells to make more virus—and
(ii) indirect costs which include the metabolic and resource costs of mounting an immune response, reduced expenditure on other fitness
enhancing functions, and friendly fire tissue damage from the response itself [54]. Hosts can evolve a variety of strategies to reduce the fitness
costs of infection. These include behavioral immunity—including avoidance behavior (social distancing) triggered by overt signs of disease.
Hosts can also evolve immune resistance strategies to clear or eliminate infections—these immune strategies are typically met with countera-
daptations on the part of fast-evolving pathogens, in an arms-race scenario that has been described as the Red Queen effect [55]. If host im-
mune defenses are excessive, causing excessive resources and/or friendly fire damage, hosts would be able to reduce expenditure in those self-
defeating responses and be rewarded with better survival and increased fitness. If available, this last option is the low hanging fruit, providing
an easily evolved way for the host to mitigate reduced fitness during infections. Unlike arm-races, it does not elicit a compensatory evolved re-
sponse of the part of the pathogen. It also allows the host to avoid reproductive or other costs of behavioral immune activation. For this reason,
medical interventions targeting excessive immune reactions are unlikely to improve outcomes, unless special circumstances exist.
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in part because of tradeoffs between defenses against viral and
bacterial infections. One such tradeoff is exemplified by FUT2
gene loss of function mutations that are common in many
human populations. These FUT2 variants confer protection
against influenza A and other viral pathogens at the cost of
increased susceptibility to various pathogenic bacteria, includ-
ing Streptococcus pneumoniae, reviewed in [53] (Box 1).
CYTOKINE STORMS AND LIFE HISTORY THEORY
Most COVID-19 infections are minimally symptomatic and self-
limiting. Some patient characteristics increase the risk of more
severe manifestations. An evolutionary perspective may shed
light on certain life history characteristics of patients who are
most at risk for a dysregulated immune response, or a potential
cytokine storm. In this section we build on the insights of
McDade [56] and others who have proposed a population-
based life-history perspective on immune development.
Children under 20 are less than half as likely to be susceptible
to symptomatic COVID-19 infection than adults over 20 [57].
Children are also more often exposed to respiratory viruses
than adults [58] and hence likely exhibit immune cross-
protection from other coronaviruses [59]. Evidence has also
shown that children have greater amounts of isolated lymphoid
follicles and Peyer’s patches (containing naı̈ve T cells and regu-
latory T cells) in their gut which diminish greatly over time [60].
This could help explain the greater sensitivity to ingested anti-
gens (food allergies) seen in children compared with adults [61]
and potentially increased susceptibility to specific inflammatory
syndromes such as Kawasaki’s disease. For cytokine responses
in particular, T-cell intracellular cytokines tend to increase with
age in healthy children [62]. TNF-a concentrations in stimulated
samples also increase with age. [63].
Some functional differences in the pediatric immune system
can be explained by life history theory. Considering all sources
of infection, pediatric infectious mortality is highest at age 0–1,
and is relatively high in early childhood (age 1–5), compared
with later ages. High infectious mortality in early life may drive
selection for accelerated lymphocyte clonal evolution in infancy
and early childhood [56]. Prioritization of early lymphocyte ex-
pansion is reflected in the size of the thymus gland, which is
greatest in infancy and disappears completely by early adult-
hood [56]. This phenomenon, termed thymic involution, is in
line with hypothesis that strong selective pressure very early in
life, i.e. in utero, generates T cells that are in place before signifi-
cant exposure to harmful microbes occurs [64].
Irrespective of the cause of death, natural selection has
decreasing power with age, a relationship that is one explan-
ation for the evolution of aging. The fitness benefit of an effect-
ive immune response of children is high until maturity, and
then it declines with increasing age. (The same is true for any
organ—functioning typically declines with increasing age after
reproductive maturity). Inflammatory responses that are con-
strained by age-related organ decline might explain why certain
inflammatory responses have higher amplitude in children and
young adulthood. Fever exhibits this pattern [65]. IFN responses
also decrease with age [66].
In addition to age, sex influences immunity and the risk of in-
fection. Men have greater mortality from infection compared
with women throughout the lifespan [67]. Increasing evidence
suggests significant differences in immunity across sex. Studies
dating to 1942 have shown that female mice are capable of pro-
ducing more antibodies than male counterparts [68].
Furthermore, sexual dimorphism, in both adaptive and innate
immunity, has been demonstrated with testosterone generally
showing an immunosuppressive effect, whereas estrogen has
shown an immunoenhancing effect [69]. Although behavioral
differences may drive some sex-specific infectious mortality,
male-biased infectious mortality begins in infancy when behav-
ior is similar, suggesting a physiological basis for infection se-
verity [67].
A variety of evolutionary hypotheses are proposed for these
sexual distinctions in immunity, based on life history theory and
sexual selection [70, 71]. Sex differences in reproductive strategy
are proposed to underlie differences in immune responses and
infection vulnerability [71]. Males die more often from infection,
reflecting a tradeoff between immune investment and anabolic
and maintenance costs of muscle, driven by the hormone tes-
tosterone [72]. Relatively increased immune vigilance in females
is protective against infection. However, higher immune vigi-
lance is also hypothesized to potentially overshoot, contributing
to disproportionate prevalence of autoimmune diseases in
women [71].
Given these known immunological differences, it is signifi-
cant to note that the populations that fare best with COVID-19
infection tend to be women and children [73, 74]. Meanwhile,
patient groups known to have poorer immune responses, such
as adult men and elderly adults, have shown to suffer more se-
vere COVID-19 disease. These patterns in COVID-19 outcomes
are paradoxical if we accept that excessively exuberant immune
responses are responsible for severe COVID-19 cases. This
leads us to believe that the emphasis on hyperinflammation as
a treatment target may miss the mark. Instead, an inadequate
or delayed initial immune response may set into motion events
that lead to severe COVID-19 infection, and those impairments
are more likely to occur in males and in older patients (Box 2).
SUPPORTING INSTEAD OF SUPPRESSING
IMMUNE RESPONSES
One key example of how the immune defenses of COVID-19
can be understood as a double-edged sword is in the
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contradictory research on IFN as a potential target of treatment.
One JAK-STAT inhibitor, tofacitinib, is currently under study for
COVID-19. Tofacitinib inhibits IFN-a in vitro [79], providing the
basis for its potential use for a cytokine storm. Targeting IFN,
though, raises a red flag. Inhibition of IFN has been shown to
be deleterious in other infections and may be similarly problem-
atic in COVID-19 [80].
Recent work on SARS-COV-2 has revealed that inhibition of
IFN is a primary virulence strategy of the virus [44]. Like the ori-
ginal SARS-COV, non-structural proteins encoded by the SARS-
COV-2 genome have the functional effect of reducing IFN early
in infection. In a recent study comparing the virological differen-
ces between SARS-COV and SARS-CoV-2, SARS-CoV-2 was spe-
cifically found to potently antagonize IFN-I [81]. Additionally,
patients with genetic polymorphisms that result in impaired
IFN responses have higher mortality from COVID-19 [82]. These
findings suggest that it is potentially dangerous to use a treat-
ment that disables a key antiviral defense, acting in the precise
mechanism of action as the virus itself.
IFNs induce a wide array of gene expression, including genes
coding for the antiviral protein vipirin. These antiviral effector
functions are important in the defense against multiple viruses
[83]. In line with the antiviral defense function of IFN, interven-
ing to augment or stimulate the IFN response early on in infec-
tion may have therapeutic effects. A small exploratory study of
77 patients infected with SARS-CoV-2 showed treatment with
IFN-a2b shortened the duration of viral shedding [84]. Another
Phase 2 trial showed that the addition of injectable IFN-b-1b, in
combination therapy, was effective in suppressing the shedding
of SARS-CoV-2 [85]. Further, the British pharmaceutical com-
pany Synairgen published results from a trial of a novel inhaled
INF-b-1a drug, SNG001. Patients randomized to SNG001
showed a greater odds of disease improvement (based on
WHO Original Scale of Clinical Improvement) compared with
those receiving placebo [85].
These observations suggest that suppressive approaches to
limiting inflammation in COVID-19 could have unintended con-
sequences in some vulnerable patients. Instead of inhibiting
these responses, supporting them may sometimes be a better
strategy. This notion is in line with the argument offered by
Remy et al. [86]. They write:
if SARS-CoV-2 infection is similar to other chronic
inflammatory and immune suppressive diseases,
such as sepsis, we argue that immune stimulants,
and not anti-inflammatory agents, should be con-
sidered as the first-line treatment option.
CONCLUSION AND FUTURE DIRECTIONS
A maladaptive host response in the setting of a novel COVID-19
infection is possible because of evolutionary novelty and mis-
match, since selection has had insufficient time to modify host
immune characteristics. However, available evidence does not
suggest that dysregulated immunity, or cytokine storms in par-
ticular, present a promising target of treatment for most
infections.
Cytokine storms are a conceptual frame, or hypothesis, that
comes with testable predictions. The most important prediction
that follows this hypothesis is that anti-cytokine therapies
should increase survival in diseases where cytokine storms are
thought to occur. Overall, recent trials have had mostly negative
Box 2. Kawasaki disease and multisystem inflammatory syndrome in children
The Kawasaki disease-like illness, known as Multisystem inflammatory Syndrome in Children (MIS-C), may be an example of an immune over-
reaction from COVID-19. Descriptions of MIS-C were first reported in April 2020 during the peak of COVID-19 activity in Europe, when a signifi-
cant population of children with hyperinflammatory shock was reported in England. As of 29 July 2020, the Centers for Disease Control in the
USA had reported 570 cases of MIS-C with 99.1% of these patients having received a positive SARS-CoV-2 serology or RT-PCR test [75].
Although MIS-C shares features with Kawasaki disease, a rare immune disorder that damages blood vessels and the heart, key differences exist.
Many more children with MIS-C present in shock compared with Kawasaki patients (50% vs 5%) [76]. Additionally, MIS-C patients have higher
ferritin, D-Dimers, and triglycerides than in Kawasaki disease, suggesting a separate pathogenesis [77].
MIS-C appears to occur after the virus has been largely cleared by the immune system, indicating it may be a post-infectious phenomenon [78].
Based on the relationship of MIS-C to SARS-CoV-2 infection it has been suggested that the pathogenesis of MIS-C involves a post-infectious im-
mune overreaction. This hypothesis has been supported by the fact that MIS-C mirrors severe COVID-19 complications in adult patients, which
coincide with a decline of viral load and increased markers of hyperinflammation in the respiratory tract [76].
It is possible that MIS-C represents an overreaction of the immune system to the novel SARS-CoV-2 virus for reasons that fit within our evolu-
tionary medicine framework. For one, the pediatric immune system has been shown to be so efficient at corralling SARS-CoV-2, that it may be
more apt to overreact, causing autoimmunity in MIS-C as a late sequela. It is also possible that due to recent host-switching of SARS-CoV-2
from bats to humans, the pediatric immune system has not had sufficient time to evolve an optimal adaptive immune response to this novel
virus.
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results from agents that reduce pro-inflammatory cytokines
(Figure 2). The inability of these drugs to improve COVID-19
mortality in randomized controlled trials casts some doubt on
the hypothesis that cytokine storms are responsible for lethal
COVID-19. Targeting cytokine storms should perhaps be de-
emphasized in favor of approaches that support host protective
immunity [86]. Alternatively, future treatments might focus on
inhibiting the pathogen, not the host immune response [86].
These strategies include targeting viral evasion of immunity
and using antiviral agents that reduce damage attributed to
widespread infection of tissues [87]. This logic supports the use
of drugs like remdesivir, an agent that targets and inhibits RNA
viral synthesis and was recently approved by the FDA to treat
COVID-19 [88].
The philosopher George Santayana wrote: ‘Those who cannot
remember the past are condemned to repeat it’. Evolution and
the recent history of medical trials have played out on different
timescales—and yet when considering immunomodulatory
interventions, we seem to have amnesia when it comes to both.
Because of the complexity of the immune system and the legacy
of selection acting on it, we should not expect that throwing a
wrench into the system will often provide a meaningful fix. Even
when cytokine storms are believed to cause mortality, the ma-
jority of trials aimed at hyperinflammation over several decades
have not produced meaningful improvements in survival.
Cytokine storms, when and if they occur, need more than a
mechanistic explanation; they need a special case exemption,
and an evolutionary rationale—for example, the mismatch hy-
pothesis proposed by Crespi [44].
SUMMARY
Progress in understanding and treating COVID-19 and cytokine
storms requires placing the disease in the appropriate historical
and evolutionary context: most anti-cytokine interventions have
failed to improve outcomes because natural selection has
shaped these responses to maximize benefits and minimize
costs. Applying life history theory to COVID-19 may prove useful
in understanding the demographic patterns of disease and po-
tentially identifying groups who might benefit from immune-
directed treatments.
Immune defenses are well-developed complex systems that
reflect millions of years of selection imposed by parasites, and
by the fitness costs of the immune response and embedded
tradeoffs. We need to be careful in assigning pathology (as in
fever), or excess (as in cytokine storms) or dysregulation (as in
sepsis) to these responses.
Conflict of interest: The authors declare that they have no con-
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